Skip To Main Content
Silas Inman on Muck Rack

Silas Inman

New York, United States
As seen in: MJH Life Sciences, NewsBreak, HCP Live, Contagion Live, American Journal of Managed Care, Pharmacy Times, ONCOLOGY journal, CURE Magazine, OncLive, Medical Economics, NeurologyLive and
Chief Brand Officer @MJHLifeSciences focused on innovative, audience-driven results @OncLive @MedEconomics @AJMC_Journal @Pharmacy_Times @MDMagazine plus more
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Silas

Contact Silas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ASCO Annual Meeting: Breast Cancer

|
By Ariana Pelosci Verified, Silas Inman, Paolo Tarantino
| ONCOLOGY journal Verified
Sacituzumab govitecan plus pembrolizumab maintained PFS improvements vs chemotherapy plus pembrolizumab in first-line metastatic TNBC. Results from the phase 3 lidERA Breast Cancer trial demonstrated a 35% reduction in the risk of invasive disease or death with giredestrant in this breast cancer population. The assay may identify a group comprising approximately two-thirds of patients who do not have a meaningful chance of benefit from adjuvant chemotherapy.
Open in Who Shared Issue with article?

Adjuvant Atezolizumab Shows Minimal Impact on Functioning/QOL in MIBC

|
By Roman Fabbricatore, Russ Conroy, Silas Inman
| ONCOLOGY journal Verified
A patient-report outcome (PRO) analysis from the phase 3 IMvigor011 trial (NCT04660344) revealed that treatment with ctDNA-guided adjuvant atezolizumab (Tecentriq) provided minimal impact on functioning and quality of life (QOL) vs placebo among patients with muscle invasive bladder cancer (MIBC), according to findings presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Open in Who Shared Issue with article?

Tocilizumab Supports Outpatient Bispecific Antibody Use in Multiple Myeloma

|
By Russ Conroy, Roman Fabbricatore, Silas Inman
| ONCOLOGY journal Verified
A single dose of prophylactic tocilizumab (Actemra) reduced the incidence of cytokine release syndrome (CRS) and supported the community-based outpatient administration of bispecific antibodies like talquetamab-tgvs (Talvey) and teclistamab-cqyv (Tecvayli) among those with relapsed/refractory multiple myeloma, according to a presentation on findings from the phase 2 OPTec/OPTal trial (NCT05972135) at the 2026 American Society of Clinical Oncology Annual Meeting (ASCO).
Open in Who Shared Issue with article?
See all 248 licensed articles (830 Total)